All In Biotech

Drug Trial Radar · NCT05667987

Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.

Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Jan 18, 2024

Primary completion

Jan 18, 2026

Study completion Feb 28, 2026

Sponsor

Lead sponsor
GCS Ramsay Santé pour l'Enseignement et la RechercheAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is, in a population of patients undergoing ERCP surgery, treated preventively with NSAIDs and divided into two groups according to the absence (group 1) or presence (group 2) of intravenous lidocaine in the general anesthesia protocol. The main objective of this study is to compare the incidence of post-ERCP pancreatitis between the two groups. type of study: clinical trial participant population/health conditions: Patients with ERCP surgery

Conditions

  • ERCP Surgery

Interventions

  • Intravenous lidocaine administrationDrug

    General anesthesia with intravenous lidocaine administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma lipase levelTime frame: Hour 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Privé des Peupliers

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.